848 related articles for article (PubMed ID: 26373573)
21. cGAS/STING Pathway in Cancer: Jekyll and Hyde Story of Cancer Immune Response.
Bose D
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29156566
[TBL] [Abstract][Full Text] [Related]
22. cGAS-STING, an important pathway in cancer immunotherapy.
Jiang M; Chen P; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; Ye L; He Y; Zhou C
J Hematol Oncol; 2020 Jun; 13(1):81. PubMed ID: 32571374
[TBL] [Abstract][Full Text] [Related]
23. Targeting STING for cancer immunotherapy: From mechanisms to translation.
Huang R; Ning Q; Zhao J; Zhao X; Zeng L; Yi Y; Tang S
Int Immunopharmacol; 2022 Dec; 113(Pt A):109304. PubMed ID: 36252492
[TBL] [Abstract][Full Text] [Related]
24. Ectopic expression of cGAS in
Waanders L; van der Donk LEH; Ates LS; Maaskant J; van Hamme JL; Eldering E; van Bruggen JAC; Rietveld JM; Bitter W; Geijtenbeek TBH; Kuijl CP
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072345
[TBL] [Abstract][Full Text] [Related]
25. A General Biomineralization Strategy to Synthesize Autologous Cancer Vaccines with cGAS-STING Activating Capacity for Postsurgical Immunotherapy.
Li Q; Dong Z; Cao Z; Lei H; Wang C; Hao Y; Feng L; Liu Z
ACS Nano; 2023 Jun; 17(11):10496-10510. PubMed ID: 37184402
[TBL] [Abstract][Full Text] [Related]
26. Targeting Cytosolic Nucleic Acid-Sensing Pathways for Cancer Immunotherapies.
Iurescia S; Fioretti D; Rinaldi M
Front Immunol; 2018; 9():711. PubMed ID: 29686682
[TBL] [Abstract][Full Text] [Related]
27. Role of the cGAS-STING pathway in cancer development and oncotherapeutic approaches.
Khoo LT; Chen LY
EMBO Rep; 2018 Dec; 19(12):. PubMed ID: 30446584
[TBL] [Abstract][Full Text] [Related]
28. The cGas-Sting Signaling Pathway Is Required for the Innate Immune Response Against Ectromelia Virus.
Cheng WY; He XB; Jia HJ; Chen GH; Jin QW; Long ZL; Jing ZZ
Front Immunol; 2018; 9():1297. PubMed ID: 29963044
[TBL] [Abstract][Full Text] [Related]
29. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer.
Cheng N; Watkins-Schulz R; Junkins RD; David CN; Johnson BM; Montgomery SA; Peine KJ; Darr DB; Yuan H; McKinnon KP; Liu Q; Miao L; Huang L; Bachelder EM; Ainslie KM; Ting JP
JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429378
[TBL] [Abstract][Full Text] [Related]
30. Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies.
Zhang J; Yu S; Peng Q; Wang P; Fang L
Cancer Biol Med; 2024 Jan; 21(1):45-64. PubMed ID: 38172538
[TBL] [Abstract][Full Text] [Related]
31. STING Activation and its Application in Immuno-Oncology.
Lian Y; Duffy KJ; Yang J
Curr Top Med Chem; 2019; 19(24):2205-2227. PubMed ID: 31642767
[TBL] [Abstract][Full Text] [Related]
32. STING activation in cancer immunotherapy.
Su T; Zhang Y; Valerie K; Wang XY; Lin S; Zhu G
Theranostics; 2019; 9(25):7759-7771. PubMed ID: 31695799
[TBL] [Abstract][Full Text] [Related]
33. Innate Immune Activation by cGMP-AMP Nanoparticles Leads to Potent and Long-Acting Antiretroviral Response against HIV-1.
Aroh C; Wang Z; Dobbs N; Luo M; Chen Z; Gao J; Yan N
J Immunol; 2017 Dec; 199(11):3840-3848. PubMed ID: 29084836
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological Modulation of the STING Pathway for Cancer Immunotherapy.
Berger G; Marloye M; Lawler SE
Trends Mol Med; 2019 May; 25(5):412-427. PubMed ID: 30885429
[TBL] [Abstract][Full Text] [Related]
35. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.
Deng L; Liang H; Xu M; Yang X; Burnette B; Arina A; Li XD; Mauceri H; Beckett M; Darga T; Huang X; Gajewski TF; Chen ZJ; Fu YX; Weichselbaum RR
Immunity; 2014 Nov; 41(5):843-52. PubMed ID: 25517616
[TBL] [Abstract][Full Text] [Related]
36. STING Activator c-di-GMP-Loaded Mesoporous Silica Nanoparticles Enhance Immunotherapy Against Breast Cancer.
Chen YP; Xu L; Tang TW; Chen CH; Zheng QH; Liu TP; Mou CY; Wu CH; Wu SH
ACS Appl Mater Interfaces; 2020 Dec; 12(51):56741-56752. PubMed ID: 33305564
[TBL] [Abstract][Full Text] [Related]
37. Rationale for stimulator of interferon genes-targeted cancer immunotherapy.
Rivera Vargas T; Benoit-Lizon I; Apetoh L
Eur J Cancer; 2017 Apr; 75():86-97. PubMed ID: 28219022
[TBL] [Abstract][Full Text] [Related]
38. Assessing the cGAS-cGAMP-STING Activity of Cancer Cells.
Pépin G; Gantier MP
Methods Mol Biol; 2018; 1725():257-266. PubMed ID: 29322423
[TBL] [Abstract][Full Text] [Related]
39. TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN.
Temizoz B; Kuroda E; Ohata K; Jounai N; Ozasa K; Kobiyama K; Aoshi T; Ishii KJ
Eur J Immunol; 2015 Apr; 45(4):1159-69. PubMed ID: 25529558
[TBL] [Abstract][Full Text] [Related]
40. TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors.
Francica BJ; Ghasemzadeh A; Desbien AL; Theodros D; Sivick KE; Reiner GL; Hix Glickman L; Marciscano AE; Sharabi AB; Leong ML; McWhirter SM; Dubensky TW; Pardoll DM; Drake CG
Cancer Immunol Res; 2018 Apr; 6(4):422-433. PubMed ID: 29472271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
